|
|
News
CryoCath Introduces Arctic Front in Hong Kong
Montreal, June 4, 2008 - CryoCath® Technologies Inc., the global leader in cryotherapy
products to treat cardiac arrhythmias, today announced the introduction of
Arctic Front® in Hong Kong. Arctic Front, the company’s lead product
for the treatment of paroxysmal atrial fibrillation (PAF), is a unique
cryoablation balloon catheter that allows physicians to safely and effectively
isolate all four pulmonary veins in the treatment of PAF.
Dr. Ngai-Yin
Chan, Head of the Electrophysiological Department at the Princess Margaret
Hospital, Hong Kong performed the first procedures on May 28, 2008. Dr. Chan had
previously attended the Arctic Front Masters Program for the cryoballoon system
in Bad Neustadt, Germany. Leadership of this program is in the hands of
Professor Dr. Burghard Schumacher and Dr. Marcus Koller, Herz-und Gefäß-Klinik.
Professor Schumacher and Dr. Koller, co-authors of The Cryoballoon Prospective
Three Center Study, are two of the most experienced users of the Arctic Front
system and are responsible for having trained in excess of sixty physicians on
circumferential pulmonary vein isolation with Arctic Front.
“In Arctic
Front, we see the potential for a groundbreaking therapy in the treatment of
paroxysmal atrial fibrillation. Our belief in cryoablation with the experience
we have has been reinforced by a growing body of clinical evidence in Europe and
throughout the world,” said Dr. Chan. “We are eager to offer Arctic Front as a
potentially safe and effective treatment to the thousands of patients in Hong
Kong suffering from atrial fibrillation.”
“We are extremely proud to see
Arctic Front expand into new markets beyond Europe, first in Australia, and now
in Hong Kong. With our rapidly growing body of clinical evidence, we are
confident that our Arctic Front system will continue to broaden its user base,”
said Jan Keltjens, President and CEO of CryoCath. “I am greatly encouraged by
the support demonstrated by leaders in Hong Kong’s medical community. By
strengthening our footprint in Asia, we look forward to delivering the benefits
of our breakthrough therapy to a wider patient base, which will in turn
accelerate the adoption of the Arctic Front system worldwide.”
Arctic
Front will be exclusively distributed in Hong Kong by Pacific Medical (HK) Co.
Ltd.
About Arctic Front
Arctic Front is a minimally
invasive cryo-balloon catheter designed specifically to treat paroxysmal Atrial
Fibrillation. This bi-directional, double balloon catheter enables physicians to
rapidly isolate all four pulmonary veins for the treatment of AFib. Over 2,600
patients have been treated in over 45 centres across Europe.
About Medtronic CryoCathCryoCath - www.cryocath.com - is a medical technology company that leads the
world in cryotherapy products to treat cardiac arrhythmias. With a priority
focus on providing physicians with a complete solution of catheter products to
treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S.,
across Europe and several ROW countries. The Company is developing additional
products to expand its pipeline of products to treat cardiac
arrhythmias.
This press release includes "forward-looking statements"
that are subject to risks and uncertainties, including with respect to the
timing of regulatory trials and their outcome. For information identifying
legislative or regulatory, economic, climatic, currency, technological,
competitive and other important factors that could cause actual results to
differ materially from those anticipated in the forward looking statements, see
CryoCath's annual report available at www.sedar.com under the heading Risks and
Uncertainties in the Management's Discussion and Analysis section.
For further information, please contact:
|
|
